PGZ Stock Chart & Stats
€0.24
€0.00(0.00%)
At close: 4:00 PM EDT
€0.24
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.17 - €0.62
Previous CloseN/A
Volume0.00
Average Volume (3M)186.00
Market Cap
€196.71M
Enterprise Value€1.21B
Total Cash (Recent Filing)€67.20M
Total Debt (Recent Filing)€998.70M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Feb 24, 2027EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding726,178,800
10 Day Avg. Volume59
30 Day Avg. Volume186
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.65
Price to Sales (P/S)0.21
P/FCF Ratio1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.28Price Target Upside18.73% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€875.45M
Bulls Say, Bears Say
Bulls Say
Persistent Free Cash FlowPersistent positive operating and free cash flow, including during recent loss-making years, shows that the core business continues converting activity into liquidity. The FY2026 improvement strengthens capacity to fund operations internally, support deleveraging, and withstand periods of weaker reported earnings.
Deleveraging ProgressMeaningful debt reduction improves Healius’s financial resilience and lowers the burden carried by future cash flows. Moderating debt-to-equity provides greater flexibility for operations and capital allocation, although the benefit is partly offset by the company’s contracted equity base.
Revenue RecoveryThe recovery in revenue demonstrates renewed top-line activity after the FY2023 contraction and provides a stronger operating base for restoring profitability. Sustained volume or service demand would improve fixed-cost absorption and create a foundation for more durable earnings recovery.
Bears Say
Sustained Net LossesFour consecutive years of net losses indicate that revenue scale has not yet translated into dependable shareholder earnings. Continued losses can consume equity, restrict internally funded investment, and leave Healius more dependent on operational improvement to rebuild long-term financial strength.
Unstable ProfitabilityThe wide variation in operating performance makes the earnings base difficult to rely on over the next several quarters. Thin or near-breakeven operating results leave limited protection against execution pressure, while weak margins reduce the benefit of the recent revenue rebound.
Contracted Equity And Negative ReturnsA smaller equity base reduces financial capacity to absorb further losses and makes balance-sheet recovery more important. Deeply negative recent returns also show that the business has not been generating adequate value from invested capital, despite progress in reducing debt.
Healius Limited News
PGZ FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest stock price was €0.17 and its highest was €0.61 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is €196.71M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Feb 24, 2027 which is in 122 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Aug 18, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of <€0.001 by -€0.002.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited does not currently pay dividends.
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is >-0.01.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,178,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -€0.002 in its last earnings report, missing expectations of <€0.001. Following the earnings report the stock price went down -7.813%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in DE:PGZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.28 (18.73% Upside)
€0.28 (18.73% Upside)
Blogger Sentiment
Bullish
DE:PGZ Sentiment 93%
Sector Average 66%
Sector Average 66%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.63%
12-Months-Change
Fundamentals
Return on Equity
-114.08%
Trailing 12-Months
Asset Growth
-13.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Healius Limited
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
PGZ Stock 12 Month Forecast
Average Price Target
€0.28
▲(18.73% Upside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―








